Nanogen Inc.

Zahlen für das 4. Qu.: Umsätze 1,015 Mio. $ (ggü. 2,078 im Vergleichsquartal), Verlust 11,198 Mio. $ oder 0.31 $ p/Sh (ggü. 5,944 oder 0.25 $ p/SH im Vergleichsquartal). Jahreszahlen: Umsätze 5,374 Mio. $ (ggü. 6,713 Mio. $ in 2003), Verlust 38,907 Mio. $ oder 1.21 $ p/Sh (ggü. 30,596 Mio. $ oder 1.38 $ p/Sh in 2003), Cashbestand 51,9 Mio. $.

die frage ist nur wie weit geht sie noch zurück
der untere boden ist wohl bei ca.2,50€?

...ca 2,90 €, wenns weiter runter geht dann bis ca 2,50 € wie du schon sagtest.
Ich hab die Aktie seit 30.12.04 auf meiner Watchlist (damals 5 €).
Die Q4 Zahlen waren zwar nicht so gut,aber:
...Das Unternehmen legte dar, sich im abgelaufenen Quartal auf eigene Produktentwicklungen und die Übernahme von Epoch Biosciences konzentriert zu haben. Im laufenden Geschäftsjahr sollen die Umsätze deshalb mindestens dreimal so hoch liegen wie im Vorjahr...
( www.boerse-go.de/news/news.php?ida=205239&idc=18 )

Mal abwarten...

Today a Doji was formed. This shows indecision about the direction of the market and it represents a tug-of-war between buyers and sellers.

The last two candlesticks formed a Bullish Harami Cross Pattern . This is a bullish reversal pattern that marks a potential change in trend. However, its reliability is not very high and it requires confirmation.

americanbulls.com/...ompanyTicker=NGEN&MarketTicker=NASD&TYP=S  

bigcharts.marketwatch.com/charts/...gs=1&rand=2921&mocktick=1" style="max-width:560px" >

www.wallstreet-online.de/market/charts/...on&gb=1d&1109439041" style="max-width:560px" >

LOL

Leider geht mein Internet Explorer nicht deshalb kann ich die Zeichnung nicht kopieren, von der Webseite.

www.americanbulls.com/...nyTicker=NGEN&MarketTicker=NASD&TYP=S
NGEN
NANOGEN INC SAN DIEGO CA
Daily Commentary

Our system posted a BUY-IF today. The previous SELL recommendation that was confirmed was made on 02.01.2005 (25) days ago, when the stock price was 5.1000. Since then NGEN has fallen -20.00% .

Is this finally a good time to buy? Well, it depends. First check what happened at after hours trading and future values. Then, follow the next session very carefully and be on your toes. This candlestick pattern is a bullish one, but we have to see whether it will be confirmed or not.

Do you see a gap-up at the market open? Do you see a white candlestick forming with a higher close at the session's end? Shortly, is it a nice bullish day? If so, place your buy orders and open new long positions. The market is now on the bull side.

But, be careful, also. If you see a gap-down when the market opens, or if the session closes with a bearish sentiment producing a black candlestick characterized by a lower close, do not challenge the market. Ignore the BUY-IF alert. Cancel the buy orders and cover any new long positions that you might have opened. Bears are still in control.

[MOTTO OF THE DAY]
Buy only if the bulls are in charge
Forget about it if the bears surge


Data provided by:  End of Day Data
          §  
BUY-IF
Conformance Rating
          §
4.0800
+0.0200 +0.49%
Candlestick Analysis
Today’s Candlestick Patterns:

Doji
Bullish Harami Cross
          §
Candlestick Pattern


Today a Doji was formed. This shows indecision about the direction of the market and it represents a tug-of-war between buyers and sellers.
For more about this candlestick click here.

The last two candlesticks formed a Bullish Harami Cross Pattern . This is a bullish reversal pattern that marks a potential change in trend. However, its reliability is not very high and it requires confirmation.
For more about this pattern click here.

Click Here!

vor Handelsende, kommt der Wert noch mal kräftig
unter druck ?

diese News kamen :



24.05.2005
Nanogen erhält 2 neue Patente
Die Aktien von Nanogen können im vorbörslichen Handel von der Meldung des Erhalts von zwei Patenten im Bereich der Bioforschung sowie der Nukleinsäue deutlich profitieren. Wie das Unternehmen am Dienstag weiter mitteilte, erhöht sich damit das Portfolio von US-Patenten auf 128. Nanogen legen vorbörslich um 7% auf 3,99 USD zu
(boerse-go.de, wirtschaftsblatt:online Partner)

'In previous government grant programs, Nanogen greatly reduced the size of its instrument and integrated essential biological sample preparation, amplification and detection technologies to design a sample-to-answer diagnostic system,' said Howard C. Birndorf, Nanogen's chairman of the board and CEO. 'This NIAID/NIH research program will further the design of a sophisticated prototype assay and instrument system and sepsis and pneumonia detection panels to help physicians expedite test results in the hospital lab and make better treatment decisions.'

Mortality from sepsis can range from 28 to 50%. In addition, pneumonia remains the seventh leading cause of death in the U.S. Estimates of the incidence of CAP range from 4 to 5 million cases per year. Early identification and appropriate treatment of the underlying cause of sepsis and pneumonia will improve patient outcomes.

About Nanogen, Inc.

Nanogen's advanced diagnostics provide researchers, clinicians, physicians and patients worldwide with improved methods and tests that can predict, diagnose and ultimately help treat disease. Nanogen's products include real-time PCR reagents, the NanoChip(R) Molecular Biology Workstation platform for molecular diagnostic applications and its line of rapid point-of-care diagnostic tests. Nanogen's ten years of pioneering research involving nanotechnology may also have future applications in medical diagnostics, biowarfare and other industries. For additional information please visit Nanogen's website at www.nanogen.com.

'Our second quarter's results were consistent with those of the previous quarter demonstrating the stability of our financial model following the integration of two acquisitions. We have built a good foundation on which new products and further acquisitions can be added,' said Howard C. Birndorf, Nanogen's chairman of the board and chief executive officer. 'We are eagerly anticipating the shipment of new products later this fiscal year that will help us grow our revenue base and set the stage for significant growth during 2006.'

Nanogen recently made an equity investment in Jurilab, a Finnish company that has developed a rich database of genetic markers over the past twenty years. The investment is the latest step in implementing Nanogen's strategy to create an advanced diagnostics company with proprietary content, market-leading solutions, and a robust platform technology. Through its new alliance, Nanogen will acquire certain rights to develop unique diagnostic products based on genes and gene markers discovered by Jurilab. Jurilab's initial efforts have focused on cardiovascular and metabolic diseases including adult onset diabetes.

Webcast of Today's Conference Call

Nanogen management will host a conference call today to discuss the preliminary second quarter 2005 results at 4:30 p.m. Eastern Time (1:30 p.m. Pacific). Audio of management's presentation will be available via live webcast on the investor relations section of Nanogen's corporate web site at www.nanogen.com, and will be archived for 90 days. A digital recording of the call will also be available for 48 hours, beginning two hours after the completion of the conference call on August 2, and can be accessed via telephone at (877) 660-6853 for US/Canada participants, and (201) 612-7415 for international participants. The account number, 286, along with the conference ID, 162458, will be required to listen to the playback.

About Nanogen, Inc.

Nanogen's advanced diagnostics provide researchers, clinicians and physicians worldwide with improved methods and tests to predict, diagnose and ultimately help treat disease. The company's products include real-time PCR reagents, the NanoChip(R) Molecular Biology Workstation platform for molecular diagnostic applications and a line of rapid point-of-care diagnostic tests. Nanogen's ten years of pioneering research involving nanotechnology holds the promise of miniaturization and continues to be supported for its potential for diagnostic and biowarfare applications. For additional information please visit Nanogen's website at www.nanogen.com.

Forward-Looking Statement

This press release contains forward-looking statements that are subject to risks and uncertainties, including statements regarding future financial and operating performance and projections regarding growth. These forward-looking statements are based on current expectations and speak only as of the date hereof. Actual results may differ materially from those set forth in the forward-looking statements, as a result of various factors and uncertainties, including whether Jurilab's technology will be successfully commercialized, whether patents owned or licensed by Nanogen will be developed into products, whether the patents owned by Nanogen offer any protection against competitors with competing technologies, whether products under development can be successfully developed and commercialized, and whether unforeseen problems may impact the timing of planned product launches, and other risks and uncertainties discussed under the caption 'Factors That May Affect Results' and elsewhere in Nanogen's Form 10-K or Form 10-Q most recently filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.



                               NANOGEN, INC.
                        CONSOLIDATED BALANCE SHEETS
              (in thousands, except par value and share data)

                                                    As of         As of
                                                  June 30,    December 31,
                                                    2005          2004
                            ASSETS               (unaudited)
    Current assets:
     Cash and cash equivalents                     $18,824       $15,372
     Short-term investments                         13,051        36,562
     Receivables, net of allowance for doubtful
      accounts of $70 and $176 at June 30, 2005
      and December 31, 2004, respectively            2,334         2,023
     Inventories, net                                2,274         1,744
     Other current assets                            2,253         1,741

      Total current assets                          38,736        57,442

    Property and equipment, net                      8,101         8,500
    Acquired technology rights, net                 10,587        11,819
    Restricted cash                                  1,411         1,411
    Other assets, net                                  804           780
    Goodwill                                        96,178        96,072

      Total assets                                $155,817      $176,024

            LIABILITIES AND STOCKHOLDERS' EQUITY
    Current liabilities:
     Accounts payable and accrued liabilities       $7,653        $9,923
     Deferred revenue                                  442           420
     Common stock warrants                             275         1,112
     Current portion of debt obligations               874           988

      Total current liabilities                      9,244        12,443

    Debt obligations, less current portion             658           610
    Other long-term liabilities                      5,508         5,455

      Total long-term liabilities                    6,166         6,065

    Stockholders' equity:
     Convertible preferred stock, $0.001 par value,
      5,000,000 shares authorized; no shares issued
      and outstanding at June 30, 2005 and
      December 31, 2004                                 --            --
     Common stock, $0.001 par value,
      135,000,000 shares authorized at June 30,
      2005 and December 31, 2004; 47,859,967 and
      47,765,581 shares issued and outstanding at
      June 30, 2005 and December 31, 2004,
      respectively                                      48            48
     Additional paid-in capital                    375,404       374,910
     Accumulated other comprehensive loss             (115)         (174)
     Deferred compensation                            (868)       (1,184)
     Accumulated deficit                          (233,140)     (215,162)
     Treasury stock, at cost, 500,189 shares at
      June 30, 2005 and December 31, 2004,
      respectively                                    (922)         (922)

      Total stockholders' equity                   140,407       157,516

      Total liabilities and stockholders'
       equity                                     $155,817      $176,024




                               NANOGEN, INC.
                   CONSOLIDATED STATEMENTS OF OPERATIONS
                                (unaudited)
                   (in thousands, except per share data)

                                  Three Months Ended     Six Months Ended
                                       June 30,               June 30,
                                  2005         2004      2005       2004
    Revenues:
     Product sales               $1,078        $477     $2,288     $1,609
     License fees and royalty
      income                      1,623          38      3,323        190
     Sponsored research              --         125         --        500
     Contracts and grants           434         478        700        978
    Total revenues                3,135       1,118      6,311      3,277

    Costs and expenses:
     Cost of product sales        1,128       1,940      2,274      2,854
     Research and development     5,160       4,040     10,072      8,388
     Selling, general and
      administrative              6,410       4,234     12,377      7,809
     Charge for acquire
      in-process research and
      development                    --       3,758         --      3,758
     Amortization of purchased
      intangible assets             392          --        785         --
    Total costs and expenses     13,090      13,972     25,508     22,809

    Loss from operations         (9,955)    (12,854)   (19,197)   (19,532)

    Other income (expense):
     Interest income, net           309         129        488        231
     Other expense                  (22)       (147)      (110)      (167)
     Warrant valuation
      adjustment                    (44)         --        837         --
     Gain on foreign currency
      translation                    (9)        (17)         4      1,204
    Total other income              234         (35)     1,219      1,268

    Net loss                    $(9,721)   $(12,889)  $(17,978)  $(18,264)

    Net loss per share --
     basic and diluted           $(0.20)     $(0.39)    $(0.38)    $(0.61)

    Number of shares used in
     computing net loss per
     share -- basic and
     diluted                     47,783      32,798     47,778     29,870

SOURCE Nanogen, Inc.